Reader response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease
Citation Manager Formats
Make Comment
See Comments

I read with interest the Null Hypothesis article by Meyer et al.1 In 2001, Weggen et al.2 suggested that flurbiprofen and ibuprofen had an effect on gamma secretase not shared by other cyclooxygenase inhibitors. This finding, along with several other failed studies of anti-inflammatory mechanisms in Alzheimer disease (AD), suggests that the widely replicated epidemiologic findings of nonsteroidal anti-inflammatory drug (NSAID) benefit for decreasing AD risk could be related to the effect on gamma-secretase, not inflammation. A flurbiprofen study failed to show a benefit for patients with AD,3 but a considerable number of studies suggest that the NSAID-related benefit requires years of treatment before dementia develops, which the study by Meyer et al.1 was appropriately targeting. However, the question remains as to whether ibuprofen is the drug to test, not naproxen.
Accurate measurement in early AD is also problematic. The failure to find an effect with the Alzheimer Progression Score, with quite large variability bars, suggests that tools for much more accurate assessments of early AD effects are needed.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2020 American Academy of Neurology
References
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.